Key Takeaways
- Spravato (esketamine) is FDA-approved for treatment-resistant depression and carries well-documented short-term side effects, including dissociation, dizziness, and temporary increases in blood pressure.
- Every patient is required to be monitored on-site by a healthcare provider for at least two hours after each dose, which is how most side effects are managed safely.
- Spravato is chemically related to ketamine but is not the same as recreational ketamine use; it's a regulated, FDA-approved medication administered under direct clinical supervision.
- The required monitoring period exists specifically because most side effects occur and resolve within that window.
- Foundation Psychiatry in Atlanta offers SPRAVATO® treatment for treatment-resistant depression, and you can schedule a consultation to see if it's the right option for you.
What Side Effects Should You Expect?
Spravato's FDA prescribing information outlines the most common side effects reported in clinical trials. According to the FDA label, patients treated with Spravato most commonly reported dissociation, dizziness, nausea, sedation, vertigo, reduced sensation (hypoesthesia), anxiety, lethargy, increased blood pressure, vomiting, and a 'feeling drunk' sensation.
These effects are generally short-lived. Dissociation, when it happens, tends to be most pronounced in the first 30 minutes after dosing. Sedation typically peaks within 30 to 60 minutes and resolves over the following hour. Blood pressure can rise temporarily and is checked specifically to confirm it comes back down before a patient leaves the office.
It's worth noting that these effects can happen at any dose, even if a previous dose was well-tolerated, which is part of why every single session, not just the first one, includes supervised monitoring.
Why Is In-Office Monitoring Required?
Because of the risks associated with sedation, dissociation, and (rarely) respiratory depression, the FDA requires Spravato to be administered only through a restricted distribution program called the Spravato REMS (Risk Evaluation and Mitigation Strategy). Under this program:
- Spravato must be administered under the direct observation of a healthcare provider.
- Patients must be monitored on-site for at least two hours after every dose.
- Blood pressure is checked around 40 minutes post-dose and again as needed until it returns to baseline.
- Patients cannot drive themselves home and must arrange transportation in advance.
This isn't a one-time requirement that eases up after your first few visits. It applies at every session, because the side effects most associated with Spravato occur within this same window each time.
Comparing the Spravato Monitoring Timeline
| Time After Dosing | What's Typically Happening |
|---|---|
| 0–30 minutes | Dissociation effects tend to be most pronounced |
| 30–60 minutes | Sedation effects typically peak |
| ~40 minutes | Blood pressure check performed |
| 90 minutes–2 hours | Most remaining side effects (dizziness, nausea, 'feeling drunk') resolve |
| 2 hours | Provider assesses readiness for discharge |
Most patients are cleared to leave at the two-hour mark. In cases where side effects are still present, providers may extend monitoring until symptoms resolve.
Is Spravato the Same as Recreational Ketamine?
This is one of the most common misconceptions patients have, and it's an understandable one, since esketamine (the active ingredient in Spravato) is chemically related to ketamine. But there are important distinctions:
- Spravato is FDA-approved specifically for depression, following extensive clinical trials, whereas ketamine itself is only FDA-approved as an anesthetic; its use for depression is off-label.
- Spravato is administered in a controlled clinical setting with standardized dosing, direct supervision, and required monitoring, not in an unsupervised or recreational context.
- The dissociative effects that make headlines around recreational ketamine use ('bad trips') are specifically why Spravato requires supervised administration. When used outside of a clinical setting without monitoring, similar substances carry meaningfully different risks.
In short, sharing a chemical relative doesn't mean sharing the same safety profile, regulatory status, or clinical use.
Is Spravato Safe for Treatment-Resistant Depression?
Spravato is FDA-approved for adults with treatment-resistant depression, either on its own or alongside an oral antidepressant, and for depressive symptoms in adults with major depressive disorder accompanied by acute suicidal thoughts, when combined with an oral antidepressant. This approval was based on multiple clinical trials evaluating both effectiveness and safety, and it comes with a defined, standardized safety protocol (the REMS program described above) specifically because regulators determined the treatment's benefits outweigh its risks when administered under proper supervision.
That doesn't mean it's risk-free, which is exactly why the monitoring protocol exists. But it does mean the risks are well-characterized, actively managed, and consistent with what's expected for a treatment this effective for a condition that hasn't responded to other options.
Feel Confident Before Starting Spravato at Foundation Psychiatry
Committing to a new treatment is easier when you know exactly what to expect. Spravato's side effects are well-documented, closely monitored, and generally short-lived, and Foundation Psychiatry's team walks every patient through the process before their first dose.
If you're considering Spravato for treatment-resistant depression, schedule a consultation with Foundation Psychiatry to learn more about SPRAVATO® treatment and whether it's the right next step for you.
Frequently Asked Questions
Is Spravato safe?
Spravato is an FDA-approved treatment with a well-documented side effect profile, most of which is short-term and resolves within the required two-hour monitoring period. It's administered under a strict federal safety program (the Spravato REMS) specifically designed to manage its risks.
What are the most common Spravato side effects?
The most commonly reported side effects include dissociation, dizziness, nausea, sedation, vertigo, and temporary increases in blood pressure. These effects are usually most noticeable in the first 30 to 90 minutes after dosing.
Why do I have to stay for two hours after each Spravato dose?
The two-hour monitoring period exists because that's the window in which most Spravato side effects occur and typically resolve. This requirement applies to every dose, not just your first, per FDA guidelines.
Is Spravato the same as the ketamine used recreationally?
No. Spravato contains esketamine, which is chemically related to ketamine but is FDA-approved specifically for depression and administered under direct medical supervision with standardized dosing. Recreational ketamine use lacks this regulation, supervision, and clinical dosing structure.
How do I know if Spravato is right for me?
Spravato is typically considered for adults with treatment-resistant depression who haven't responded to other antidepressants. A consultation with a psychiatric provider is the best way to determine whether you're a good candidate.
